Survival advantage associated with metformin usage in hepatocellular carcinoma patients receiving radiotherapy: A propensity score matching analysis

Anticancer Research

Volumn 35, Issue 9, 2015, Pages 5047-5054

  Jang, Won Il ^a   Kim, Mi Sook ^a   Lim, Jung Sub ^a   Yoo, Hyung Jun ^a   Seo, Young Seok ^a   Han, Chul Ju ^a   Park, Su Cheol ^a   Kay, Chul Seung ^b   Kim, Myungsoo ^b   Jang, Hong Seok ^b   Lee, Dong Soo ^b   Chang, Ah Ram ^c   Park, Hae Jin ^d  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

^d Hanyang University College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; Metformin; Radiotherapy; Survival

Indexed keywords

METFORMIN;

ADULT; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; AGED; CARCINOMA, HEPATOCELLULAR; COHORT ANALYSIS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED;

AGED; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; METFORMIN; MIDDLE AGED; PROPENSITY SCORE; TREATMENT OUTCOME;

EID: 84939634598     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Schütte K, Bornschein J and Malfertheiner P: Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 27: 80-92, 2009.
2. Klein J and Dawson LA: Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys 87: 22-32, 2013.
3. Wong R and Frenette C: Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol 7: 16-24, 2011.
4. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA and Cardenes HR: Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 81: e447-453, 2011.
5. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, Bae SH, Jung da H, Kim KB, Lee DH, Han CJ, Kim J, Park SC and Kim YH: Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 118: 5424-5431, 2012.
6. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ and Dawson LA: Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31: 1631-1639, 2013.
7. Jang WI, Kim MS, Bae SH, Cho CK, Yoo HJ, Seo YS, Kang JK, Kim SY, Lee DH, Han CJ, Kim J, Park SC, Kim SB, Cho EH and Kim YH: High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 8: 250, 2013.
8. Kim YI, Park HC, Lim Do H et al: Changes of the liver volume and the Child-Pugh score after high-dose hypofractionated radiotherapy in patients with small hepatocellular carcinoma. Radiat Oncol J 30: 189-196, 2012.
9. Kourelis TV and Siegel RD: Metformin and cancer: new applications for an old drug. Med Oncol 29: 1314-1327, 2012.
10. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ and Dennis PA: Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 24: 469-480, 2013.
11. Lund SS: Metformin and mortality. Diabetologia 56: 937-938, 2013.
12. Zhang P, Li H, Tan X, Chen L and Wang S: Association of metformin use with cancer incidence and mortality: a metaanalysis. Cancer Epidemiol 37: 207-218, 2013.
13. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M and Li D: Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18: 2905-2912, 2012.
14. Spillane S, Bennett K, Sharp L and Barron TI: A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. Cancer Epidemiol Biomarkers Prev 22: 1364-1373, 2013.
15. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC and Fleshner N: Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31: 3069-3075, 2013.
16. Kumar S, Meuter A, Thapa P, Langstraat C, Giri S, Chien J, Rattan R, Cliby W and Shridhar V: Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 119: 555-562, 2013.
17. Skinner HD, Crane CH, Garrett CR, Eng C, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Kelly P, Sandulache VC, Delclos ME, Krishnan S and Das P: Metformin use and improved response to therapy in rectal cancer. Cancer Med 2: 99-107, 2013.
18. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK and Myers JN: TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 18: 290-300, 2012.
19. Vazquez-Martin A, Olivera-Ferraros C, Cuf? S, Del Barco S, Martin-Castillo B and Menendez JA: Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 9: 3807-3814, 2010.
20. Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco S, Martin-Castillo B and Menendez JA: Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA LET-7a and suppression of the TGF?-induced oncomiR miRNA-181a. Cell Cycle 10: 1144-1151, 2011.
21. Liu J, Hou M, Yuan T, Yi G, Zhang S, Shao X, Chen J, Jia X and He Z: Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair. Oncol Rep 28: 1406-1412, 2012.
22. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: 52-60, 2010.
23. Rosenbaum P and Rubin DB: The central role of the propensity score in observational studies for causal effect. Biometrika 70: 41-55, 1983.
24. Austin PC: Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10: 150-161, 2011.
25. Lipsey MW and Wilson DB: Practical Meta-Analysis (Applied Social Research Methods Series, Volume 49). Thousand Oaks, CA, US: SAGE Publications, pp. 172-206, 2000.
26. Austin PC: A Tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality. Multivariate Behav Res 46: 119-151, 2011.
27. Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS and Zhang RM: Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Radiother Oncol 92: 184-194, 2009.
28. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN and Gonzalez-Angulo AM: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297-3302, 2009.
29. Chen TM, Lin CC, Huang PT, Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 26: 858-865, 2011.
30. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN and Guerrero TM: Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52: 1002-1009, 2013.
31. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z and Zelefsky MJ: Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 63: 709-716, 2013.
32. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN and Gonzalez-Angulo AM: Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118: 1202-1211, 2012.
33. Zannella VE, Pra AD, Muaddi H, McKee TD, Stapleton S, Sykes J, Glicksman R, Chaib S, Zamiara P, Milosevic M, Wouters BG, Bristow RG and Koritzinsky M: Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res 19: 6741-6750, 2013.
34. ClinicalTrials.gov: A Phase III Randomized Trial of Metformin vs. Placebo in Early Stage Breast Cancer. https://clinical trials.gov/ct2/show/NCT01101438. Accessed 9 Mar 2015
35. Qu Z, Zhang Y, Liao M, Chen Y, Zhao J and Pan Y: In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res 42: 922-933, 2012.
36. Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz JC, Singh G, Wright J and Tsakiridis T: Ionizing radiation activates AMPactivated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys 78: 221-229, 2010.
37. Carlson DJ, Keall PJ, Loo BW Jr., Chen ZJ and Brown: Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys 79: 1188-1195, 2011.
38. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Lopez-Bonet E and Menendez JA: The antidiabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncol Rep 25: 135-140, 2011.
39. Rattan R, Graham RP, Maguire JL, Giri S and Shridhar V: Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13: 483-491, 2011.
40. Nitta T, Kim JS, Mohuczy D and Behrns KE: Murine cirrhosis induces hepatocyte epithelial-mesenchymal transition and alterations in survival signaling pathways. Hepatology 48: 909-919, 2008.
41. Wang YG, Wang P, Wang B, Fu ZJ, Zhao WJ and Yan SL: Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One 9: e95485, 2014.